Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mary Jo Laffler

Executive Editor, US Commercial/R&D

Mary Jo oversees a talented team analyzing business and clinical activity for Scrip, Pink Sheet and In Vivo. Since starting as a reporter in 2000, Mary Jo has held editor positions across Pink Sheet and the former Pink Sheet DAILY and Pharmaceutical Approvals Monthly, and covered the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. Mary Jo helped create the FDA Performance Tracker charts as a way to use regulatory data to aid development decisions and better understand agency patterns, and continues to enjoy working with data to identify industry trends through features and infographics. She frequently moderates webinars and panels at conferences. An avid reader, Mary Jo volunteers as a literacy tutor and is on the board of the local library.

Latest From Mary Jo Laffler

Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus

Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

Deal Watch Business Strategies

Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs

Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.

Deals M & A

How Biogen’s Aduhelm Bet Became A Commercial Bust

Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later. 

Launches Market Access

How Biogen’s Aduhelm Bet Became A Commercial Bust

Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later. 

Launches Market Access

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion
See All
UsernamePublicRestriction

Register